from PharmaTech.com by: Randi Hernandez Hospira announced on Oct.1, 2014 that it received a warning letter from FDA regarding its manufacturing plant in Mulgrave, Australia. In the letter, FDA reprimanded the manufacturer for not addressing “significant violations of current good manufacturing practice” the agency observed earlier in the year. According to FDA, Hospira failed to […]